10/622,010

Application Number

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

TRANSMITTAL
FORM
(to be used for all correspondence after initial filing)

July 16, 2003 **Filing Date** Joseph Monforte **First Named Inventor** 1743 Group Art Unit Unassigned **Examiner Name**

Total Number of	f Pages in This Subm	ission		Attorney Docket Numbe	r	47-030010US
ENCLOSURES (check all that apply)						
Fee Transmi	ittal Form	As (fo	ssignm or an A	ent Papers pplication)		After Allowance Communication to Group
Fee A	ttached	Dr	rawing	(s)		Appeal Communication to Board of Appeals and Interferences
Amendment	t / Response	Lie	censin	g-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After	r Final	Pe an	etition I nd Acc	Routing Slip (PTO/SB/69) ompanying Petition		Proprietary Information
Affid	avits/declaration(s)	111		to Convert to a nal Application		Status Letter
Extension of	f Time Request		ower of hange ddress	f Attorney, Revocation of Correspondence	X	Additional Enclosure(s) (please identify below):
Express Aba	andonment Request			Disclaimer		Cited References and receipt acknowledgment postcard Form 1449
X Information I	Disclosure Statement			ntity Statement for Refund		701 MITT
	ppy of Priority	Authoriza	tion to	Charge Deposit Account		
Document(s Response to Incomplete	o Missing Parts/	this paper	or duri	eposit Account No. 50-0893 ng the pendency of this appl of the documents enclosed.	for any ication	additional fees associated with including any extensions of time
l	conse to Missing	Remar	rks			1.144.00
Parts	s under 37 CFR or 1.53	<u> </u>		J		
	SIGNATU	RE OF A	PPLIC	CANT, ATTORNEY, OR	AGE	NT .
Firm <i>or</i> Individual name	Gwynedd Warre	en, Reg. N	No. 45	5,200, Quine Intellectua	l Pro	perty Law Group, P.C.
Signature	Leuyne	addi	Par	·		
Date	12/1/03					
CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope						

12-1-2003 addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Evelyn Gomez	· ·		
Signature	Ellery		Date	12-1-2003



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313-1450, on 12-1-200

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Evelyn Gomez

Attorney Docket No. 47-030010US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joseph Monforte, et al.

Application No.: 10/622,010

Filed: July 16, 2003

For: STRATEGIES FOR GENE

EXPRESSION ANALYSIS

Examiner: Unassigned

Art Unit: 1743

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Joseph Monforte, et al.

Application No.: 10/622,010

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Gwynedd Warren Reg. No. 45,200

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458 Alameda, CA 94501 (510) 337-7871 Fax (510) 337-7877 Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A-B/PTO **Application Number** 10/622,010 Filing Date July 16, 2003 NEORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor **Joseph Monforte** Group Art Unit 1743 **Examiner Name** Unassigned DEC 4 2003 e as many sheets as necessary) Attorney Docket Number 47-030010US **Date Submitted** December 1, 2003

PADER			U.	S. PATENT DOCUMENTS		
Examiner Initials	Cite No.	U.S. Patent Doc Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	1	5,143,854		Pirrung et al.	09-01-1992	
	2	5,807,522		Brown et al.	09-15-1998	
	3	5,545,522		Van Gelder et al.	08-13-1996	
	4	5,595,895		Miki et al.	01-21-1997	
	5	5,962,271		Chenchik et al.	10-05-1999	
·	6	6,087,102		Chenchik et al.	07-11-2000	
	7	6,251,639		Kurn	06-26-2001	
	8	6,287,768		Chenchik et al.	09-11-2001	
	9	6,489,159		Chenchik et al.	12-03-2002	

				FOREIGI	N PATENT DOCUMEN	TS		
Examiner Cite	Cite	Foreign Patent Document Kind Code			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т
Initials	No.	Office	Number	(if known)	Applicant of Cited Document	MM-DD-YYYY	or Relevant Figures Appear	<u> </u>
	10	wo	99/35289		Clontech Laboratories, Inc.	07-15-1999		
	11	wo	01/55454		Genetrace Systems, Inc.	08-02-2001		

	Y	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	12	EBERWINE, Amplifications of mRNA Populations Using aRNA Generated from Immobilized Oligo (dT)-T7 Primed cDNA, Biotechniques 20: 584-591 (1996).	
	13	FODOR et al., Light-Directed Spatially Addressable Parallel Chemical Synthesis, Science 251:767-773 (1991).	
	14	PUSKAS et al., RNA Amplification Results in Reproducible Microarray Data with Slight Ratio Bias, Biotechniques 32:6; 1330-1334 (2002).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid divide control number.					
C	omplete if Known				
Application Number	10/622,010				
Filing Date	July 16, 2003				
First Named Inventor	Joseph Monforte				
Group Art Unit	1743				
Examiner Name	Unassigned				
Attorney Docket Number	47-030010US				
Date Submitted	December 1, 2003				
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number				

	15	SCHENA et al., Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray, Science 270:467-470 (1995).	
	16	THOMAS et al., Identification of Toxicologically Predictive Gene Sets Using cDNA Microarrays, Molecular Pharmacology 60: 1189-1194 (2001).	
	17	VAN'T VEER et.al., Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer, Nature 415: 530-536 (2002).	
,	18	VAN GELDER et al., Amplified RNA Synthesized from Limited Quantities of Heterogeneous cDNA, Proc. Natl. Acad. Sci. USA 87:5; 1663-1667 (1990).	

	•		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.